Evaluation of the Edaravan Effect on the outcomes ain patients with acute ischemic stroke

Evaluation of the Edaravan Effect on the outcomes and oxidative stress parameters in patients with acute ischemic stroke: a clinical trial study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210602051472N1

Enrollment

Registered

2021-06-20

Start date

2021-07-23

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Intervention group: In this group, in addition to standard treatment, a dose of Edaravan (Zist daroo danesh Company) starts with a dose of 0.16 ml per weight and continues with a dose

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Focal neurological symptoms due to cerebrovascular involvement in less than 24 hours Older age 18 years Stroke is approved by CT or MRI. The severity of the stroke should be greater than 4 by the NIHSS criteria and the patient's ability scale before the stroke should be less than 2. It should be noted that it is also injected at intensities higher than 24. The patient is inclined to enter the study

Exclusion criteria

Exclusion criteria: Hemorrhagic stroke Transient stroke Brain Tumor Inflammatory diseases and demyelinating brain History of craniotomy Previous severe brain trauma Liver and kidney failure Pregnancy and lactation Acute heart attack Allergy to the drug Adaravan

Design outcomes

Primary

Measure	Time frame
Modified Rankin Score (MRS). Timepoint: At the time of discharge and three months after the intervention. Method of measurement: The ability of patients, which is mainly assessed after 90 days by checklist.;NIH Stroke Scale/Score (NIHSS). Timepoint: At the time of discharge and three months after the intervention. Method of measurement: check list.;ESR measurement. Timepoint: At the time of discharge and three months after the intervention. Method of measurement: Blood Samples, Green Blot Method.;CRP Measurement. Timepoint: At the time of discharge and three months after the intervention. Method of measurement: Blood Samples, Immuno-agglutination Assay.	—

Measure

Time frame

Modified Rankin Score (MRS). Timepoint: At the time of discharge and three months after the intervention. Method of measurement: The ability of patients, which is mainly assessed after 90 days by checklist.;NIH Stroke Scale/Score (NIHSS). Timepoint: At the time of discharge and three months after the intervention. Method of measurement: check list.;ESR measurement. Timepoint: At the time of discharge and three months after the intervention. Method of measurement: Blood Samples, Green Blot Method.;CRP Measurement. Timepoint: At the time of discharge and three months after the intervention. Method of measurement: Blood Samples, Immuno-agglutination Assay.

—

Secondary

Measure	Time frame
Side effects of treatment. Timepoint: After discharge and three months after intervention. Method of measurement: checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Saadatipour

Hamedan University of Medical Sciences

Dr.fatemehsaadatypour@gmail.com+98 81 3838 0030

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026